Group items tagged

At Pharma CI Conference 2015 in New Jersey, Best Practices, LLC's CEO, Chris Bogan discussed the topic: Blockbuster Drugs Launch Evolution: Mapping Market - Entry Changes That Cause New Products to Stumble or Soar.

This report summary is an overview of the full report published by Best Practices, LLC. The report includes insights and information about the new pharmaceutical drugs launch spend in medical affairs in the US market.

Teva Pharmaceutical Industries has launched the generic equivalent to Xeloda tablets, 150mg and 500mg, in the US.

RainTree Oncology Services and Information Builders have launched OncoExplorer, a new cloud-based analytics portal that offers unprecedented decision-support capabilities to pharmaceutical companies.

Fycompa (perampanel), the first in an entirely new class of treatment for partial onset seizures (the most common form of epilepsy), will be launched in the Netherlands on 13 May 2014.

Published 25 February 2014 Cambridge Healthtech Associates (CHA) has announced a new program to accelerate innovation in life sciences and health care. Announcing the launch of the first-ever tool in life sciences and health care to evaluate and rank new technologies and services via an end-user process.

EMA will launch a final round of targeted consultations with key stakeholders on its draft policy on proactive publication of and access to clinical-trial data at the beginning of May 2014.

Best Practices (BPs), while employed in a variety of industries, is especially valuable in the growing drug/device (DD) combination products industry. Read the article to know how drug and device start-ups get the jump on the competition by employment of best practices.